                </a></li></ul></div><p><strong>Figure 4.  <span>Administration of EcN in DSS induced colitis.</span></strong></p><a id="article1.body1.sec3.sec2.fig1.caption1.p1" name="article1.body1.sec3.sec2.fig1.caption1.p1"></a><p>(A) Disease severity was measured daily and is expressed in terms of body weight loss. (group II: n = 23, group III: n = 25, group I: n = 17) *<em>p</em>&lt;0.05 group III vs. group II. (B) Reduction of colon length. Measurement of colon length [cm] after preparation. (group II: n = 24, group III: n = 25, group I: n = 13) *<em>p</em>&lt;0.05 group III vs. group II or group III vs. group I **<em>p</em>&lt;0.01 group II vs. group I. (C) Infiltration of hematopoietic cells into the colon. Whole intestinal cell populations were labeled with anti-CD45 APC antibody and measured by FACS analysis (n = 6/group).</p>
